Business Context and Reporting Period
Trevi Therapeutics, Inc. (TRVI) filed a Current Report on Form 8-K on April 16, 2026. The filing announces the entry into a material definitive agreement for an underwritten public offering of common stock and provides a business update regarding its lead product candidate, Haduvio, for the treatment of chronic cough.
Key Financial Metrics
- Public Offering: 11,600,000 shares of common stock priced at $13.00 per share.
- Underwriting Price: $12.22 per share.
- Over-Allotment Option: Underwriters granted a 30-day option to purchase up to 1,740,000 additional shares.
- Estimated Net Proceeds: Approximately $141.1 million (base) or $162.4 million (if over-allotment is fully exercised), after deducting discounts and expenses.
- Cash Position: Approximately $171.8 million in cash, cash equivalents, and marketable securities as of March 31, 2026 (preliminary estimate).
- Revenue/Profit: The filing does not provide specific revenue, profit, or margin data for the period.
Material Changes and Liquidity
The primary material change is the execution of the underwriting agreement, which significantly increases the company's liquidity. Management estimates that existing cash resources combined with the anticipated net proceeds from the offering will fund operating expenses and capital expenditures through 2029. This runway is intended to support the development of Haduvio, including two planned Phase 3 trials for idiopathic pulmonary fibrosis (IPF) and Phase 2b trials for non-IPF interstitial lung disease and refractory chronic cough.
Outlook, Management Commentary, and Risks
Clinical Development Plan
- IPF Phase 3 Trials: Two parallel trials planned. The first (approx. 300 patients) initiates in Q2 2026 with topline data expected in H1 2028. The second (approx. 130 patients) initiates in H2 2026 with topline data expected in H2 2027.
- Non-IPF ILD Phase 2b: Adaptive design trial planned for H2 2026, with topline data expected in H2 2027.
- Refractory Chronic Cough (RCC) Phase 2b: Trial planned for Q2 2026 in the UK, Canada, and Poland (approx. 100 patients), with topline data expected in H2 2027.
Management Commentary and Risks
Management notes that the current cash runway does not include commercial launch expenses for Haduvio or funding for future product candidates beyond regulatory approval for non-IPF ILD or RCC. The company will need to raise substantial additional capital for full commercialization. Risks include the uncertainty of clinical trial success, regulatory approval timelines, and the potential for capital resources to be consumed sooner than expected.
Investor Verification Checklist
- Verify the final closing date of the offering (expected on or about April 20, 2026) and the actual net proceeds received.
- Confirm whether the underwriters exercise the 30-day over-allotment option for an additional 1,740,000 shares.
- Monitor the initiation dates of the Phase 3 IPF trials and Phase 2b trials to ensure they align with the Q2/H2 2026 schedule.
- Review the final audited financial statements for the quarter ended March 31, 2026, to validate the preliminary cash estimate of $171.8 million.
- Assess the FDA's feedback on the Phase 3 trial protocols, as trial designs are subject to final regulatory review.